Using our novel R&D platform for the advancement of life-changing medicines, we focus on neurological and endocrine based diseases and disorders.Learn More
We have a novel product approved for the treatment of adults with involuntary movements caused by exposure to dopamine receptor blocking agents.Learn More
We are investigating a first-in-class, oral treatment option that addresses the chronic, intermittent, predictable and unpredictable symptoms common to Endometriosis and Uterine Fibroids.
We are investigating a once-daily treatment for tics associated with Tourette syndrome.Learn More
We are investigating a non-steroidal therapy for Classical CAH to treat the effects of life-long elevated androgens and the use of high-dose corticosteroids both of which can lead to the virilization of females, metabolic syndrome, bone loss, growth impairment, and Cushing's syndrome.